Stomatitis and VEGFR-Tyrosine Kinase Inhibitors (VR-TKIs): A Review of Current Literature in 4369 Patients

Table 2

Report on all papers about sorafenib and stomatitis.

	Authors	Year	Neoplasia	Cases; number	Stomatitis (%)	Stomatitis; grade 1%	Stomatitis grade 2%	Stomatitis grade 3%	Stomatitis grade 4%
(1)	Cho et al. [45]	2013	Advanced hepatocellular carcinoma; A: sorafenib 400 mg twice daily	A: 99	A: 4 (4%)	Not reported		Not reported
(2)	Chrisoulidou et al. [46]	2015	Refractory thyroid cancer; Sorafenib 400 mg was given orally twice daily continuously, sunitinib 50 mg was given once daily on a 4 weeks of treatment followed by 2-week intervals without therapy, and vandetanib 300 mg was given once daily	A: 24	A: 13 (54%)	A: 12 (50%)		A: 1 (4.16%)
(3)	Grignani et al. [47]	2015	Unresectable high-grade osteosarcoma progressing after standard treatment; 400 mg sorafenib twice a day together with 5 mg everolimus once a day	A: 38	A: 20 (52.63%)	Not reported		Not reported
(4)	Hainsworth et al. [48]	2015	Stage III/IV epithelial ovarian cancer; A: paclitaxel 175 mg/m2, 1–3 h IV infusion/carboplatin AUC 6.0, 20 min IV infusion/sorafenib 400 mg PO BID	A: 43	A: 16 (37%)	Oral mucositis; A: 16 (37%)		A: 0
(5)	Hainsworth et al. [49]	2013	Phase II; Sorafenib 200 mg PO BID and everolimus 35 mg PO once weekly	A: 75	A: 10 (13.3%)	Mucositis/stomatitis: 10/14%; Mucositis/stomatitis: 2/3%		Mucositis/stomatitis: 0; Mucositis/stomatitis: 0
(6)	Lee et al. [6]	2009	Retrospective study; A: sorafenib 400 mg twice daily for RCC and HCC; B: sunitinib 50 mg daily, consisting of 4 weeks of treatment followed by a 2-week rest period in cycles of 6 weeks for RCC and GIST	A: 109; B: 119	A: 28 (26%); B: 43 (36%)	Not reported		Not reported
(7)	Marschner et al. [33]	2017	mRCC; A: sorafenib; B: sunitinib	A: 25; B: 152	A: 3 (12.0%); B: 29 (23.2%)	A: 2 (8%); B: 27 (17.7%)		A: 1 (4.0%); B: 2 (1.6%)
(8)	Meyer et al. [50]	2017	Unresectable HCC; A: sorafenib 660 mg	A: 157	A: 41 (26%)	A: 36 (23%)		A: 5 (3%)
(9)	Porta et al. [51]	2011	mRCC; A: sunitinib; B: sorafenib	A: 85; B: 60	A: 50 (58.8%); B: 16 (26.7%)	A: 48 (56.4%); B: 16 (26.7%)		A: 2 (2.4%); B: 0
(10)	Richly et al. [52]	2006	Refractory solid tumors; A: sorafenib 100 mg + doxorubicin; B: sorafenib 200 mg + doxorubicin; C: sorafenib 400 mg + doxorubicin; D: sorafenib 400 mg + doxorubicin	A: 6; B: 6; C: 12; D: 10	TOT 11 (32%)	Not reported		A: 3 (50%); B: -; C: 6 (50%); D: 2 (20%)
(11)	Schwartzberg et al. [53]	2013	Advanced breast cancer; A: sorafenib (400 mg, twice daily)	A: 79	A: 27 (34.1%)	A: 17 (21.5%)		A: 10 (12.65%)
(12)	Shacham-Shmueli et al. [54]	2012	Advanced solid tumors; A: sorafenib 100 mg BID (50 mg tablets) + infusion regimen; B: sorafenib 200 mg BID (50 mg tablets) + infusion regimen; C: sorafenib 400 mg BID (50 mg tablets) + infusion regimen; D: sorafenib 400 mg BID (50 mg tablets) + bolus A regimen; E: sorafenib 400 mg BID (200 mg tablets) + infusion regimen; F: sorafenib 400 mg BID (200 mg tablets) + bolus B regimen	A: 10; B: 7; C: 6; D: 9; E: 6; F: 9	A: -; B: -; C: -; D: 3 (33%); E: -; F: -	Not reported		A: -; B: -; C: -; D: 3 (33%); E: -; F: -
(13)	Sho et al. [55]	2017	Advanced hepatocellular carcinoma; A: 250 mg/m^2 of 5-FU and sorafenib 800 mg daily; B: 350 mg/m^2 of 5-FU and sorafenib 800 mg daily; C: 450 mg/m^2 of 5-FU and sorafenib 800 mg daily	A: 3; B: 3; C: 6	A: 0; B: 1; C: 3	A: 0; B: 1; C: 2		A: -; B: -; C: 1
(14)	Ueda et al. [56]	2013	Metastatic renal cell carcinoma; A: axitinib; B: sorafenib	A: 359; B: 355	A: 54 (15.04%); B: 44 (12.39%)	A: 49 (13.64%); B: 43 (12.11%)		A: 5 (1.39%); B: 1 (0.28%)
(15)	Williamson et al. [57]	2010	Advanced and metastatic squamous cell carcinoma of the head and neck; A: sorafenib orally at 400 mg twice daily on continuous basis in 28-day cycles	A: 41	A: 2 (4.9%)	Not reported		A: 2
(16)	Zhao et al. [44]	2013	Locally advanced clear cell renal carcinoma; A: sorafenib 400 mg orally twice daily for 4-week cycle; B: sunitinib 50 mg orally daily for a 6-week cycle	A: 20; B: 23	A: 8 (40%); B: 7 (30%)	Not reported		Not reported
	Total			1218	250 (20.52%)
	Total with grade			830	174 (20.96%)	155 (18.67%)		19 (2,28%)
	Total not reporting grade			266	60 (22.55%)	Not reported		Not reported
	Total reporting only grade >2			122	16 (13.11%)	Not reported		16 (13.11%)

Note. Cho et al. (2013) [45], Grignani et al. (2015) [47], Lee et al. (2009) [6], and Zhao et al. (2013) [44] did not report the grade of stomatitis; Richly et al. (2006) [52], Shacham-Shmueli et al. (2012) [54], and Williamson et al. (2010) [57] reported the incidence rates limited to grade 3 and grade 4 treatment-related toxicities; for this reason, data about cases of stomatitis and stomatitis grades 1 and 2 are lower than real.